drugset / Trial / NCT03443596

Blood Pressure Control in Acute Ischemic Stroke

NCT03443596

Phase 2/3 Completed 54 enrolled National University of Singapore
RandomizedParallel-groupSingle-blindTreatment

Summary

Management of acutely elevated blood pressure during the early phase of ischemic stroke remains controversial. In patients treated with IV-tPA, the risk of ICH is closely related to the BP levels. However, intensive reduction of BP carries a theoretical risk of clinical deterioration by inducing cerebral hypoperfusion. Assessment of cerebral perfusion before and after BP reduction is one of the most scientific method to evaluate the safety (and potential benefits) of BP management in the acute phase of stroke. This project will impact practices and delivery of BP management during the acute phase of ischemic stroke. The findings would aid in designing phase 3 clinical trials will track clinical indicators, including the impact on functional outcomes as well as quality-of-life and cost-effectiveness.

Timeline

Start
2014-12-01
Primary completion
2019-03-13
Completion
2019-03-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Labetalol Small molecule Intravenous